PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 176 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $71,000 | -4.1% | 8,000 | 0.0% | 0.00% | – |
| Q1 2021 | $74,000 | -7.5% | 8,000 | 0.0% | 0.00% | – |
| Q4 2020 | $80,000 | +2.6% | 8,000 | 0.0% | 0.00% | – |
| Q3 2020 | $78,000 | +77.3% | 8,000 | +55.1% | 0.00% | – |
| Q4 2019 | $44,000 | -71.1% | 5,158 | -62.2% | 0.00% | -100.0% |
| Q3 2019 | $152,000 | -46.1% | 13,658 | -38.4% | 0.00% | 0.0% |
| Q2 2019 | $282,000 | -38.8% | 22,158 | +111.0% | 0.00% | -66.7% |
| Q1 2019 | $461,000 | +153.3% | 10,500 | +23.5% | 0.00% | +200.0% |
| Q4 2018 | $182,000 | -60.5% | 8,500 | -19.0% | 0.00% | -66.7% |
| Q3 2018 | $461,000 | -24.3% | 10,500 | -2.8% | 0.00% | -25.0% |
| Q2 2018 | $609,000 | -21.8% | 10,800 | -8.5% | 0.00% | -20.0% |
| Q1 2018 | $779,000 | +281.9% | 11,800 | +337.0% | 0.01% | +150.0% |
| Q3 2015 | $204,000 | -32.7% | 2,700 | +3.8% | 0.00% | -50.0% |
| Q2 2015 | $303,000 | – | 2,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,792,114 | $4,713,260 | 4.15% |
| Eversept Partners, LP | 1,681,149 | $4,421,422 | 0.37% |
| Camber Capital Management LP | 4,235,000 | $11,138 | 0.37% |
| Kynam Capital Management, LP | 473,975 | $1,246,554 | 0.20% |
| GLOBEFLEX CAPITAL L P | 538,559 | $1,416,410 | 0.17% |
| Affinity Asset Advisors, LLC | 202,349 | $532,178 | 0.15% |
| GSA CAPITAL PARTNERS LLP | 279,629 | $735 | 0.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 363,666 | $956,442 | 0.06% |
| Patriot Financial Group Insurance Agency, LLC | 67,000 | $176,210 | 0.04% |
| ACADIAN ASSET MANAGEMENT LLC | 1,858,000 | $4,884 | 0.02% |